Gilead Sciences, Inc.

Gilead Sciences, Inc. Earnings Recaps

GILD Health Care 4 recaps
Next earnings: February 9, 2027 (estimated) · full calendar
Q3 2026 Nov 1, 2026

Gilead’s shares rose 3.1% after earnings, with investors responding to 16% year-over-year growth in base business sales and a $1.6 billion increase to 2026 base business revenue guidance over the course of the year. The quarter’s growth was led by HIV, though some of the sequential HIV sales increase reflected inventory dynamics that management expects to normalize by year-end.

Key takeaways
  • Total product sales excluding Veklury were $8.2 billion, up 16% year-over-year and 8% sequentially; including Veklury, sales were $8.3 billion, up 13% year-over-year.
  • HIV sales rose 18% to $6.2 billion. Biktarvy sales increased 10% to $4.1 billion and reached 53% U.S. treatment market share; favorable inventory dynamics contributed to sales growth.
  • HIV prevention sales nearly doubled year-over-year. Yeztugo and Descovy for PrEP together held 50% market share and a $4 billion annual run rate, according to management.
  • Trodelvy sales grew 42% year-over-year, reaching an approximately $2 billion annual run rate; Livdelzi also contributed to base business growth.
  • Management said the HIV treatment market had not returned to its typical 2%–3% growth, although it had shown signs of stabilization. The completed Biktarvy Medicare price determination is expected to affect revenue in 2028.
Q2 2026 Aug 7, 2026

Shares in Gilead moved modestly higher by 0.5% following the quarter, reflecting a broadly in-line result with no major surprises or disappointments despite raised HIV growth guidance.

Key takeaways
  • Total product sales (excluding Veklury) increased 10% year-over-year to $7.6 billion, driven by HIV, oncology, and liver disease businesses.
  • HIV sales grew 12% year-over-year to $5.7 billion, led by Biktarvy, Descovy, and Yeztugo; full-year HIV sales guidance was raised to 9%–10% growth from 8%.
  • PrEP sales doubled year-over-year, exceeding $1 billion for the first time with a $4 billion annual run rate, significantly outpacing the 14% growth in the U.S. prevention market.
  • Trodelvy oncology sales rose 26% year-over-year, supported by label expansions and new approvals.
  • Livdelzi liver disease sales more than doubled, and the company launched Hepcludex for hepatitis delta virus in the U.S. this quarter.
Q1 2026 May 8, 2026

Gilead’s shares fell 3.6% following earnings as investors reacted negatively to cautious near-term guidance implied by sequential sales declines and typical first-quarter seasonality, signaling deceleration despite solid year-over-year growth in key HIV products.

Key takeaways
  • Total product sales (ex-Veklury) reached $6.8 billion, up 8% year-over-year, but declined 12% sequentially, consistent with usual first-quarter inventory and channel mix effects.
  • HIV sales grew 10% year-over-year to $5.0 billion but fell 13% sequentially due to inventory normalization and lower average realized price.
  • Biktarvy HIV treatment sales increased 7% year-over-year to $3.4 billion but dropped 15% sequentially reflecting seasonal patterns.
  • Oncology continued progress with Trodelvy sales up 37% year-over-year and multiple expected regulatory catalysts in H2 2026.
  • Upcoming pipeline news and acquisitions signal longer-term growth, but near-term execution uncertainties weighed on sentiment.
Q3 2025 Oct 31, 2025

Gilead Sciences delivered robust third-quarter results, highlighting strong growth across its HIV portfolio and disciplined cost management, leading to a 22% year-over-year increase in non-GAAP EPS.

Key takeaways
  • Total product sales for Q3 reached $7.3 billion, driven mainly by an impressive 6% year-over-year growth for Biktarvy and 20% growth for Descovy.
  • Non-GAAP EPS grew by 22% year-over-year, even when excluding a $0.25 benefit from a nonrecurring accounting item.
  • Gilead boosted its full-year HIV revenue growth expectations to approximately 5%, despite facing a $900 million revenue headwind from the Medicare Part D redesign.
  • Livdelzi exceeded $100 million in quarterly sales for the first time, driving a 12% year-over-year growth in the liver portfolio.
  • The company is targeting commercial launches for Trodelvy in metastatic breast cancer and anito-cel in multiple myeloma in 2026, enhancing future growth prospects.